{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:23:02Z","timestamp":1793380982194,"version":"4.5.0"},"reference-count":37,"publisher":"Massachusetts Medical Society","issue":"4","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100031585","name":"Takeda Development Center Americas","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031585","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Seagen"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2022,7,28]]},"DOI":"10.1056\/nejmoa2206125","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T17:00:41Z","timestamp":1657731641000},"page":"310-320","source":"Crossref","is-referenced-by-count":352,"title":["Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma"],"prefix":"10.1056","volume":"387","author":[{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"D\u0142ugosz-Danecka","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallamini","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Ramchandren","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-1824","authenticated-orcid":false,"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Smolewski","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie","family":"Dong","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Campana","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keenan","family":"Fenton","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Puhlmann","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Straus","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.); BC Cancer Centre for Lymphoid Cancer, Vancouver (J.M.C., K.J.S.); Maria Sklodowska-Curie National Research Institute of Oncology, Krakow (M.D.-D.), and the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.) \u2014 both in Poland; the Division of Hematology\u2013Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (W.-S.K.), and the Department of Hematology\u2013Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang (H.-S.E.) \u2014 both in South Korea; Research and Innovation Department, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); the University of Tennessee Graduate School of Medicine, Knoxville (R.R.); Wilmot Cancer Institute, University of Rochester, Rochester (J.W.F.), and the Department ..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211193272102"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.4803"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5648"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32134-7"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00101-0"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8820"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000719"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30784-8"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.2543"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005150"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100340"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3298"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.3721"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00102-2"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.529208"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003127"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1793666"},{"issue":"5","key":"e_1_3_5_22_2","first-page":"CD007941","article-title":"Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.","volume":"5","author":"Skoetz N","year":"2017","unstructured":"Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2017;5(5):CD007941-CD007941.28541603","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115481"},{"key":"e_1_3_5_24_2","unstructured":"Cao A Heiser R Law C-L et al. Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses. In: Proceedings and abstracts of the 107th Annual Meeting of the American Association for Cancer Research April 16\u201320 2016. New Orleans: American Association for Cancer Research 2016. abstract."},{"key":"e_1_3_5_25_2","unstructured":"Gardai SJ Epp A Law C-L. Brentuximab vedotin-mediated immunogenic cell death. In: Proceedings and abstracts of the 106th Annual Meeting of the American Association for Cancer Research April 18\u201322 2015. Philadelphia: American Association for Cancer Research 2015. abstract."},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224"},{"key":"e_1_3_5_27_2","unstructured":"Li F Zhang X Emmerton K et al. Relationship between in vivo antitumor activity of ADC and payload release in preclinical models. In: Proceedings and abstracts of the 1065th Annual Meeting of the American Association for Cancer Research April 5\u20139 2014. San Diego CA: American Association for Cancer Research 2014. abstract."},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07146.x"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M510026200"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00264"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02668"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju207"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02483-8"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.138"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2014.06.008"},{"key":"e_1_3_5_36_2","unstructured":"Hague C Johnson P Federico M et al. Pulmonary function and grade 3\/4 clinical events in PET negative patients taking part in the international RATHL trial (CRUK\/07\/033): a comparison of 12 vs 4 doses of bleomycin. Hematol Oncol 2015;33:121-121. In: Proceedings and abstracts of the 13th International Conference on Malignant Lymphoma June 17\u201320 2015. Lugano Switzerland: American Association for Cancer Research 2015. abstract."},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278438"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1791846"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2206125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:12:11Z","timestamp":1749669131000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2206125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7,28]]}},"alternative-id":["10.1056\/NEJMoa2206125"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2206125","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742233905.793595094","asserted-by":"object"}]},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]}}}